---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037575"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-08-13T11:30:14+00:00"
generated_at: "2026-08-13T11:35:34.846521+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Abeona Q2 ZEVASKYN revenue up 31% QoQ to $11.4M; net loss widens to $20.2M

## Summary
- ZEVASKYN net revenue $11.4M in Q2 2026, up 31% QoQ from $8.7M in Q1; revenue recognized for 4 of 5 treated patients
- Net loss $(20.2)M ($0.35/share) vs $(17.1)M ($0.30/share) in Q1; cash $146.8M at June 30, down from $191.4M at Dec 31
- QTC network expanded to 7 sites; CHOP, NewYork-Presbyterian/Columbia activated in Q2, Cincinnati Children's in Q3
- CMS granted NTAP status for ZEVASKYN effective Oct 1, 2026, supporting hospital adoption and Medicare access
- R&D expenses fell to $5.0M from $9.6M (Q1 included $7.0M one-time ABO-701 in-licensing cost); SG&A $15.8M vs $19.5M

## SEC filing metadata
- accession: 0001493152-26-037575
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-08-13T11:30:14+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/0001493152-26-037575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037575
- JSON: https://secwatch.observer/filing/0001493152-26-037575.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.